Shares of Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) saw unusually-high trading volume on Tuesday . Approximately 15,348,587 shares changed hands during mid-day trading, an increase of 413% from the previous session’s volume of 2,991,120 shares.The stock last traded at $1.70 and had previously closed at $1.36.

Separately, Maxim Group initiated coverage on Interpace Diagnostics Group in a research note on Tuesday, August 15th. They issued a “buy” rating and a $5.00 target price on the stock.

The stock’s market cap is $35.24 million. The stock’s 50 day moving average is $1.11 and its 200 day moving average is $1.79.

Interpace Diagnostics Group (NASDAQ:IDXG) last posted its quarterly earnings results on Thursday, August 10th. The business services provider reported ($0.65) EPS for the quarter. Interpace Diagnostics Group had a negative net margin of 37.08% and a negative return on equity of 32.06%. The business had revenue of $3.86 million during the quarter.

An institutional investor recently bought a new position in Interpace Diagnostics Group stock. Susquehanna International Group LLP purchased a new stake in Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 718,076 shares of the business services provider’s stock, valued at approximately $646,000. Susquehanna International Group LLP owned about 3.84% of Interpace Diagnostics Group as of its most recent filing with the Securities and Exchange Commission (SEC). 7.58% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Interpace Diagnostics Group, Inc. (IDXG) Sees Unusually-High Trading Volume” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.